For the quarter ending 2026-03-31, PVLA had $148,412K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -15,767 | -12,714 | -11,345 | -17,656 |
| Non-cash interest expense - royalty agreement | 2,039 | 1,739 | 1,510 | 2,569 |
| Non-cash interest expense - convertible notes | - | 0 | 0 | - |
| Change in fair value of derivative liabilities - royalty agreement | 116 | 119 | 82 | 193 |
| Change in fair value of derivative liabilities - contingent value right agreement | - | - | 238 | - |
| Change in fair value of derivative liabilities - contingent value right liability | -202 | 218 | - | - |
| Change in fair value of convertible notes payable | - | 0 | 0 | - |
| Stock-based compensation | 3,376 | 2,084 | 1,790 | 2,527 |
| Accretion on marketable securities | 15 | - | - | - |
| Non-cash lease operating expense | 44 | 62 | - | - |
| Costs to issue convertible notes | - | 0 | 0 | 0 |
| Accounts receivable | - | -29 | 0 | -358 |
| German research and development tax credit receivable | - | -2,105 | - | - |
| Prepaid expenses and other current assets | 357 | -222 | -182 | -960 |
| Accounts payable | 851 | 1,156 | -1,136 | 1,240 |
| Accrued expenses and other current liabilities | -900 | 292 | 801 | -2,393 |
| Payments on operating lease liabilities | -49 | - | - | - |
| Proceeds from pipe financing | - | 0 | - | - |
| Net cash used in operating activities | -10,864 | -4,926 | -7,878 | -12,202 |
| Payments of transaction costs associated with pipe financing | - | 0 | - | - |
| Purchase of marketable securities | 55,440 | - | - | - |
| Proceeds from issuance of convertible notes | - | 0 | 0 | 0 |
| Cash acquired from reverse merger transaction | - | 0 | - | - |
| Net cash used in investing activities | -55,440 | - | - | - |
| Payment of transaction costs in connection with reverse merger | 0 | 0 | 0 | 1,269 |
| Proceeds from issuance of common stock in connection with equity financing | 230,000 | - | - | - |
| Payment of financing cost in connection with equity financing | 14,247 | - | - | - |
| Payment of transaction costs to issue convertible notes | - | 0 | 0 | 0 |
| Payment of contingent value right liability | 1,978 | - | - | - |
| Proceeds from exercise of stock options | 956 | 105 | 242 | 416 |
| Deferred equity issuance costs | - | 154 | - | - |
| Net cash provided by (used in) financing activities | 214,731 | -49 | 242 | -853 |
| Effect of exchange rate change on cash and cash equivalents | -15 | -610 | 770 | -114 |
| Net increase (decrease) in cash and cash equivalents | 148,412 | -5,585 | -6,866 | -13,169 |
| Cash and cash equivalents at beginning of period | 57,982 | 63,567 | 83,602 | - |
| Cash and cash equivalents at end of period | 206,394 | 57,982 | 63,567 | - |
PALVELLA THERAPEUTICS, INC. (PVLA)
PALVELLA THERAPEUTICS, INC. (PVLA)